A Novel RGD-4C-Saporin Conjugate Inhibits Tumor Growth in Mouse Models of Bladder Cancer.
RGD peptide
RGD-integrins
bladder cancer
recombinant protein
ribosome inactivating proteins
saporin
targeted therapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
31
12
2021
accepted:
18
03
2022
entrez:
28
4
2022
pubmed:
29
4
2022
medline:
29
4
2022
Statut:
epublish
Résumé
Although toxin may have some advantages compared to chemotherapeutic drugs in cancer therapy, e.g. a potent cytotoxic activity and a reduced risk of resistance, their successful application in the treatments to solid tumors still remains to be fully demonstrated. In this study, we genetically modified the structure of the plant-derived single-chain ribosome inactivating protein saporin (SAP) by fusing its N-terminus to the ACDCRGDCFCG peptide (RGD-4C), an αv-integrin ligand, and explored the anti-tumor activity of the resulting protein (called RGD-SAP)
Identifiants
pubmed: 35480108
doi: 10.3389/fonc.2022.846958
pmc: PMC9035931
doi:
Types de publication
Journal Article
Langues
eng
Pagination
846958Informations de copyright
Copyright © 2022 Zuppone, Assalini, Minici, Botrugno, Curnis, Degano, Corti, Montorsi, Salonia and Vago.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Toxins (Basel). 2017 Oct 12;9(10):
pubmed: 29023422
J Cell Physiol. 2018 May;233(5):4091-4105
pubmed: 28941284
N Engl J Med. 2019 Jul 25;381(4):338-348
pubmed: 31340094
Int J Mol Sci. 2017 Nov 01;18(11):
pubmed: 29104238
Toxins (Basel). 2017 Oct 27;9(11):
pubmed: 29076988
Mol Oncol. 2013 Jun;7(3):475-83
pubmed: 23298730
Eur Urol Oncol. 2019 Sep;2(5):576-583
pubmed: 31411974
Drug Resist Updat. 2005 Dec;8(6):381-402
pubmed: 16309948
J Control Release. 2007 Feb 26;117(3):342-50
pubmed: 17207883
Int J Mol Sci. 2016 Dec 06;17(12):
pubmed: 27929432
Front Pharmacol. 2015 Nov 24;6:279
pubmed: 26635609
Lab Anim. 2005 Oct;39(4):384-93
pubmed: 16197705
Science. 1995 Dec 1;270(5241):1500-2
pubmed: 7491498
Urol Oncol. 2006 Jan-Feb;24(1):58-61
pubmed: 16414496
Beilstein J Org Chem. 2018 Feb 14;14:407-415
pubmed: 29520305
Mol Pharm. 2012 Nov 5;9(11):2961-73
pubmed: 22967287
Front Pharmacol. 2021 Apr 15;12:588306
pubmed: 33935695
Sci Rep. 2020 Feb 13;10(1):2521
pubmed: 32054892
Eur Urol. 2018 Feb;73(2):226-232
pubmed: 28705539
Biomedicines. 2019 May 17;7(2):
pubmed: 31108917
Urology. 2002 Sep;60(3):531-6
pubmed: 12350512
Microb Cell Fact. 2016 Nov 14;15(1):194
pubmed: 27842546
Microb Cell Fact. 2015 Feb 13;14:19
pubmed: 25889802
Cell. 2002 Sep 20;110(6):673-87
pubmed: 12297042
J Immunother. 2008 Jan;31(1):34-42
pubmed: 18157010
Sci Rep. 2017 Jan 11;7:39805
pubmed: 28074920
Small. 2013 Mar 11;9(5):673-8
pubmed: 23143930
Toxins (Basel). 2018 Feb 13;10(2):
pubmed: 29438358
Sci Rep. 2020 Jan 29;10(1):1439
pubmed: 31996725
BJU Int. 2008 Jan;101(1):120-4
pubmed: 17888045
Cancer Res. 2004 Jan 15;64(2):565-71
pubmed: 14744770
J Clin Invest. 1995 Oct;96(4):1815-22
pubmed: 7560073
Toxicon. 2017 Sep 15;136:6-14
pubmed: 28651991
Acta Pharm Sin B. 2021 Sep;11(9):2726-2737
pubmed: 34589393
Microb Cell Fact. 2011 Dec 02;10:101
pubmed: 22136342
Toxins (Basel). 2019 Oct 11;11(10):
pubmed: 31614697
Mol Cancer Ther. 2008 May;7(5):1044-53
pubmed: 18483294
PLoS One. 2014 Sep 23;9(9):e108464
pubmed: 25247809